In view of the fact that
pancreatic cancer, called as the king of
cancer, is one of the most lethal
malignancies, exploring effective technologies for
pancreatic cancer diagnosis and
therapy remains an appealing yet significantly challenging task. Phototheranostics has recently received considerable attention by virtue of its various distinctive advantages. However, the limited penetration depth, strong
oxygen-dependence and high
heat shock protein-inhibition of conventional phototheranostic materials severely hamper their overall
theranostic efficacy, especially for deep-seated
hypoxia tumors, such as pancreatic
tumor. In this study, an aggregation-induced emission (AIE)-featured
photosensitizer, namely DCTBT, synchronously sharing NIR-II fluorescence imaging (FLI), diminished
oxygen-dependent type-I
photodynamic therapy (
PDT) and high-efficiency
photothermal therapy (PTT) functions was subtly constructed by molecular engineering. With the aid of an EGFR-targeting-
peptide-modified amphiphilic
polymer, the as-prepared DCTBT-loaded
liposomes is capable of effectively accumulating at and visualizing pancreatic
tumor, as well as significantly suppressing the
tumor growth on both subcutaneous and orthotopic PANC-1
tumor mice models. This study thus brings useful insights into designing the next generation of
cancer theranostic agents for potential clinical applications.